Lawrence G. Raisz

Lawrence G. Raisz

Auto-generated profile, based on publicly available information

Lawrence G. Raisz

Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LRLawrence G. Raisz
Lawrence G. Raisz
Osteoporosis is a disorder in which loss of bone strength leads to fragility fractures. This review examines the fundamental pathogenetic mechanisms underlying this disorder, which include: (a) failure to achieve a skeleton of optimal strength during growth and development; (b) excessive bone resorption resulting in loss of bone mass and disruption of architecture; and (c) failure to replace lost bone due to defects in bone formation. Estrogen deficiency is known to play a critical role in the development of osteoporosis, while calcium and vitamin D deficiencies and secondary hyperparathyroidism also contribute. There are multiple mechanisms underlying the regulation of bone remodeling, and these involve not only the osteoblastic and osteoclastic cell lineages but also other marrow cells, in addition to the interaction of systemic hormones, local cytokines, growth factors, and transcription factors. Polymorphisms of a large number of genes have been associated with differences in bone mass and fragility. It is now possible to diagnose osteoporosis, assess fracture risk, and reduce that risk with antiresorptive or other available therapies. However, new and more effective approaches are likely to emerge from a better understanding of the regulators of bone cell function.

14 July 2005 in New England Journal of Medicine
Verified
Journal Article
Closed access
LRLawrence G. Raisz
Lawrence G. Raisz
At her annual visit, a 60-year-old woman asks her physician whether she should have a bone-density test to screen for osteoporosis. The patient went through menopause at the age of 52 years and received postmenopausal hormone therapy for four years. She takes 500 mg of calcium twice daily and exercises regularly. She has no personal history of fractures, but her mother had a hip fracture at the age of 82. Her height is 63 in. and her weight is 120 lb. What should her physician advise?


1 July 2003 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
LRLawrence G. Raisz
Lawrence G. Raisz
FWFlorence N. Woodiel
Florence N. Woodiel

1 November 2002 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
COCheryl Oncken
Cheryl Oncken
KPKaren M. Prestwood
Karen M. Prestwood
JCJudith L. Cooney
Judith L. Cooney
CUChristine Unson
Christine Unson
PFPamela Fall
Pamela Fall
LRLawrence G. Raisz
Lawrence G. Raisz
The purpose of this study was to prospectively evaluate the impact of smoking cessation on hormonal concentrations, sex hormone-binding globulin (SHBG) and markers of bone turnover in postmenopausal women. Sixty-six women who were either users or non-users of estrogen replacement therapy (ERT) were randomly assigned, using a weighted randomization scheme, to smoking cessation (SC) or to smoking cessation after 6 weeks of monitoring (wait-list control group, WLC). We measured hormones [estrone, estradiol, testosterone, parathyroid hormone, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS) and androstenedione] and SHBG, markers of bone turnover [procollagen peptide (PINP), bone alkaline phosphatase (BAP), and osteocalcin (OC), N - and C -terminal collagen cross-links (NTx and CTx)], and cotinine, at baseline and again at 6 weeks in women who reported smoking cessation and in women randomized to the WLC group. Analyses included 20 subjects who quit or significantly reduced their smoking and 18 subjects in the WLC group. After controlling for differences in age and ERT use between groups, we found a significant change in SHBG in the SC vs. the WLC group (−8% vs. +5%, respectively; p = 0.01), and in DHEA (-18% vs. −5%, respectively; p = 0.04), but not in other hormonal concentrations. We also noted a significant change in NTx in the SC vs. WLC group (−5% vs. +56%, respectively, p = 0.01), but not in other markers of bone turnover. Percentage changes in SHBG and NTx were correlated with changes in plasma cotinine (r = 0.48; p = 0.004 and r = 0.36; p = 0.04, respectively). Six weeks of smoking abstinence produces reductions in SHBG and NTx. This may partly explain how smoking contributes to osteoporosis in postmenopausal women.

1 August 2000 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
LRL. Raisz
L. Raisz
JSJ.-A. Smith
J.-A. Smith
MTM. Trahiotis
M. Trahiotis
PFP. Fall
P. Fall
KSK. Shoukri
K. Shoukri
NSN. Sacco-Gibson
N. Sacco-Gibson